Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 5, 2004, Pages 409-414

  Patel, Aneeta ^a   Pluim, Thomas ^a   Helms, Amy ^a   Bauer, Andrew ^a,b   Tuttle, R Michael ^c   Francis, Gary L ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Capecitabine; Drug treatment; Thyroid cancer

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; ENZYME; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; ARTICLE; CANCER GRADING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TARGET ORGAN; THYROID CANCER; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PAPILLARY; CHILD; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; THYROID NEOPLASMS;

EID: 2142654975     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0732-7     Document Type: Article

References (22)

1. Ain KB, Tofiq S, Taylor KD (1996) Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653
2. Blum JL (1999) Xeloda in the treatment of metastatic breast cancer. Oncology 57 [Suppl 1]:16-20
3. Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56-64
4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493
5. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768
6. DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424
7. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
8. Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, Conran R, Francis GL (2001) Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab 86:1346-1354
9. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057; discussion 1057-1058
10. Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F, Ishitsuka H (1998) Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′- deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 21:713-717
11. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690
12. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
13. Lessin LS, Min M (2000) Chemotherapy of anaplastic thyroid cancer. In : Wartofsky L (ed) Thyroid cancer: a comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 337-340
14. Lo CY, Lam KY, Wan KY (1999) Anaplastic carcinoma of the thyroid. Am J Surg 177:337-339
15. National Cancer Institute (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. National Cancer Institute, NIH, Bethesda, MD
16. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K (2002) Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 9:479-482
17. Schmutzler C, Koehrle J (2000) Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol 143:15-24
18. Tennvall J, Andersson T, Aspegren K, Biorklund A, Ingemansson S, Landberg T, Akerman M (1979) Undifferentiated giant and spindle cell carcinoma of the thyroid. Report on two combined treatment modalities. Acta Radiol Oncol Radiat Phys Biol 18:408-416
19. Tennvall J, Tallroth E, el Hassan A, Lundell G, Akerman M, Biorklund A, Blomgren H, Lowhagen T, Wallin G (1990) Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol 29:1025-1028
20. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S (1994) Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 74:1348-1354
21. Voutilainen PE, Multanen M, Haapiainen RK, Leppaniemi AK, Sivula AH (1999) Anaplastic thyroid carcinoma survival. World J Surg 23:975-978; discussion 978-979
22. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL (1998) Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 49:619-628